Literature DB >> 18427961

Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3' diindolylmethane (DIM).

Asfar Sohail Azmi1, Aamir Ahmad, Sanjeev Banerjee, Vivek M Rangnekar, Ramzi M Mohammad, Fazlul H Sarkar.   

Abstract

PURPOSE: Cancer chemoprevention is defined as the use of natural, synthetic, or biological agents to suppress, reverse or prevent the carcinogenic process from turning into aggressive cancer. Prostate apoptosis response-4 (Par-4) is a unique pro-apoptotic protein that selectively induces apoptosis in prostate cancer cells. However, its role in other malignancies has not been fully explored. This study tries to identify the functional significance of Par-4 in pancreatic cancer.
METHODS: Multiple molecular techniques such as Western blot analysis, trypan blue assay for cell viability, MTT assay for cell growth inhibition and Histone/DNA ELISA for apoptosis were used.
RESULTS: Western blot analysis revealed that 3,3'-diindolylmethane (DIM) a chemopreventive agent, specifically its more bioavailable formulation, B-DIM, at low doses (20 micromol/L) induces Par-4, in L3.6pl and Colo-357 pancreatic cancer cells. At similar doses, DIM reduced cell viability and caused cell growth inhibition and apoptosis. Moreover, DIM pre-treatment sensitized the cells to cytotoxic action of chemotherapeutic drug gemcitabine through up-regulation of Par-4.
CONCLUSION: The induction of Par-4 is indirectly related to increased sensitivity and cell death through apoptosis. To our knowledge the results reported here showed, for the first time, the induction of Par-4 by chemopreventive agents, in general, and DIM, in particular, in pancreatic cancer cells in vitro.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18427961      PMCID: PMC3766320          DOI: 10.1007/s11095-008-9581-8

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  32 in total

Review 1.  AKT plays a central role in tumorigenesis.

Authors:  J R Testa; A Bellacosa
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

2.  3,3'-diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5.

Authors:  Maen Abdelrahim; Kristen Newman; Kathy Vanderlaag; Ismael Samudio; Stephen Safe
Journal:  Carcinogenesis       Date:  2005-12-06       Impact factor: 4.944

3.  p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma.

Authors:  C A Moskaluk; R H Hruban; S E Kern
Journal:  Cancer Res       Date:  1997-06-01       Impact factor: 12.701

Review 4.  Surgery for pancreatic cancer: recent controversies and current practice.

Authors:  Curtis J Wray; Syed A Ahmad; Jeffrey B Matthews; Andrew M Lowy
Journal:  Gastroenterology       Date:  2005-05       Impact factor: 22.682

5.  Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines.

Authors:  C Sun; T Yamato; T Furukawa; Y Ohnishi; H Kijima; A Horii
Journal:  Oncol Rep       Date:  2001 Jan-Feb       Impact factor: 3.906

6.  Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer.

Authors:  Bridget N Fahy; Michael G Schlieman; Subbulakshmi Virudachalam; Richard J Bold
Journal:  J Am Coll Surg       Date:  2004-04       Impact factor: 6.113

7.  Treatment of pancreatic cancer: challenge of the facts.

Authors:  Hans G Beger; Bettina Rau; Frank Gansauge; Bertram Poch; Karl-Heinz Link
Journal:  World J Surg       Date:  2003-08-21       Impact factor: 3.352

8.  Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells.

Authors:  Yiwei Li; Zhiwei Wang; Dejuan Kong; Shalini Murthy; Q Ping Dou; Shijie Sheng; G Prem Veer Reddy; Fazlul H Sarkar
Journal:  J Biol Chem       Date:  2007-05-23       Impact factor: 5.157

9.  Apoptosis mediated by a novel leucine zipper protein Par-4.

Authors:  V M Rangnekar
Journal:  Apoptosis       Date:  1998-03       Impact factor: 4.677

10.  High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas.

Authors:  K Grünewald; J Lyons; A Fröhlich; H Feichtinger; R A Weger; G Schwab; J W Janssen; C R Bartram
Journal:  Int J Cancer       Date:  1989-06-15       Impact factor: 7.396

View more
  26 in total

Review 1.  PAR-4 as a possible new target for pancreatic cancer therapy.

Authors:  Asfar S Azmi; Philip A Philip; Syed F Zafar; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  Expert Opin Ther Targets       Date:  2010-06       Impact factor: 6.902

Review 2.  Chemoprevention strategies for pancreatic cancer.

Authors:  Silvia D Stan; Shivendra V Singh; Randall E Brand
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-05-04       Impact factor: 46.802

3.  Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy.

Authors:  Asfar S Azmi; Philip A Philip; A Aboukameel; Zhiwei Wang; Sanjeev Banerjee; Syed F Zafar; Anton-Scott Goustin; K Almhanna; Dajun Yang; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  Curr Cancer Drug Targets       Date:  2010-05       Impact factor: 3.428

4.  Prostate apoptosis response-4 is expressed in normal cholangiocytes, is down-regulated in human cholangiocarcinoma, and promotes apoptosis of neoplastic cholangiocytes when induced pharmacologically.

Authors:  Antonio Franchitto; Alessia Torrice; Rossella Semeraro; Cristina Napoli; Gennaro Nuzzo; Felice Giuliante; Gianfranco Alpini; Guido Carpino; Pasquale Bartolomeo Berloco; Luciano Izzo; Antonio Bolognese; Paolo Onori; Anastasia Renzi; Alfredo Cantafora; Eugenio Gaudio; Domenico Alvaro
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

5.  Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis.

Authors:  Asfar Sohail Azmi; Zhiwei Wang; Ravshan Burikhanov; Vivek M Rangnekar; Guoping Wang; Jianyong Chen; Shaomeng Wang; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

Review 6.  Attenuation of multi-targeted proliferation-linked signaling by 3,3'-diindolylmethane (DIM): from bench to clinic.

Authors:  Sanjeev Banerjee; Dejuan Kong; Zhiwei Wang; Bin Bao; Gilda G Hillman; Fazlul H Sarkar
Journal:  Mutat Res       Date:  2011-06-15       Impact factor: 2.433

7.  Systems and Network Pharmacology Approaches to Cancer Stem Cells Research and Therapy.

Authors:  Irfana Muqbil; Ginny W Bao; Rkya El-Kharraj; Minjel Shah; Ramzi M Mohammad; Fazlul H Sarkar; Asfar S Azmi
Journal:  J Stem Cell Res Ther       Date:  2012-12-16

Review 8.  Mechanisms of apoptosis by the tumor suppressor Par-4.

Authors:  Nikhil Hebbar; Chi Wang; Vivek M Rangnekar
Journal:  J Cell Physiol       Date:  2012-12       Impact factor: 6.384

Review 9.  A journey beyond apoptosis: new enigma of controlling metastasis by pro-apoptotic Par-4.

Authors:  Reyaz Ur Rasool; Debasis Nayak; Souneek Chakraborty; Archana Katoch; Mir Mohd Faheem; Hina Amin; Anindya Goswami
Journal:  Clin Exp Metastasis       Date:  2016-08-27       Impact factor: 5.150

10.  3,3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer.

Authors:  Sanjeev Banerjee; Zhiwei Wang; Dejuan Kong; Fazlul H Sarkar
Journal:  Cancer Res       Date:  2009-06-16       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.